Alnylam Research on miRNAs Featured in The New England Journal of Medicine
News Mar 20, 2006
Alnylam Pharmaceuticals, Inc. has announced that its research on therapeutic silencing of microRNAs was featured in an article published in the March 16, 2006 issue of The New England Journal of Medicine.
The article titled 'MicroRNAs as Therapeutic Targets' was authored by Dr. Michael Czech, Chair of the Program in Molecular Medicine at the University of Massachusetts Medical School, and discussed clinical applications for intervening with microRNAs.
Research by Alnylam and its collaborators at The Rockefeller University has demonstrated that miRNAs can be specifically silenced by using antagomirs, a class of oligonucleotide drugs.
Alnylam believes this approach creates the opportunity to design antagomirs that target miRNAs involved in the cause or pathway of human diseases, such as cancer and viral infection.
"We're thrilled to have the importance of miRNAs and Alnylam's own work in this field recognized and reviewed in one of the world's leading medical journals," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam.
"We believe that the opportunity to target miRNAs involved in human disease with antagomirs is an important extension of our platform to harness the RNAi pathway for discovery of innovative medicines."
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?